Board summary
Key figures
49,082
Registered population
61.8% aged 18–64
17.6%
Aged 65+
ICB 19.0% · England 17.9%
7.8%
Ethnic minority (non-White)
4.1% Asian · England 9.6%
15.1%
In IMD quintile 1
ICB 31.9% · England 21.0%
~5,922
Core20 residents (est.)
Resident basis; registered basis ~9,534 · see page 3
7,262
Hypertension register
+5.89% in 3 yrs · England +5.60%
524
SMI register
23.5% of Warrington (LAD)'s
869
COPD register
Reviews +3.62% in 3 yrs
Forecast to 2030
8,455
Hypertension patients, 2030
+1,193 on today
70.9%
QRISK ≥20% on statins, 2030
+4.49pp over 3 yrs
3.8%
Cancer prevalence, 2030
England 4.5%
Three things the board should see
Asthma annual reviews trail England benchmark.
Annual review completion is 61.6% against 65.7% in England (1,185 unreviewed scale across 3,084 patients), which may reflect recall gaps to test by audit.
Three-year declines in severe mental illness checks.
Mental health register BMI recording changed by -3.6 pp (England +5.1 pp) and blood pressure checks by -1.7 pp (England +4.4 pp) over 2023.
Hypertension blood pressure control exceeds borough rate.
Patients treated to blood pressure target reach 70.1% (Warrington (LAD) 68.7%, ICB 69.1%, England 70.3%), and 83.5% in those aged 80+ (England 81.2%).
Population, age and ethnicity
Registered list of 49,082 patients has 20.6% aged 0-17 and 17.6% aged 65+
Warrington Innovation PCN has 49,082 registered patients. Patients aged 0-17 represent 20.6% (10,119), above Warrington (LAD) (19.7%), NHS Cheshire and Merseyside Integrated Care Board (19.2%), and England (19.6%). Those aged 65+ comprise 17.6% (8,632), against 17.5% in Warrington (LAD), 19.0% in NHS Cheshire and Merseyside Integrated Care Board, and 17.9% in England. Catchment Census data (resident, not registered) records 92.2% White and 4.1% Asian or Asian British (Warrington (LAD) 3.3%, NHS Cheshire and Merseyside Integrated Care Board 2.8%, England 9.6%), ranging from 7.0% at Springfields Medical Centre to 1.7% at Culcheth Medical Centre.
Age profile
65+: ICB 19.0%, England 17.9%
Ethnicity
Older people · falls rows are Warrington (LAD) local-authority (LA) data, not PCN
| Measure | Local | North West | England | Period |
|---|---|---|---|---|
| Falls admissions, 65+, per 100,000 (Warrington LA) | 1,737 | 2,071 | 1,958 | 2024/25 |
| Diabetes with frailty: HbA1c ≤75 mmol/mol (PCN) | 79.3% | 82.9% | 81.9% | 2024/25 |
| Diabetes without frailty: HbA1c ≤58 mmol/mol (PCN) | 59.1% | 56.6% | 57.4% | 2024/25 |
| Falls admissions, 65 to 79, per 100,000 (Warrington LA) | 905 | 1,021 | 955 | 2024/25 |
| Falls deaths, all ages, per 100,000 (Warrington LA) | 12.1 | 18.2 | 14.8 | 2022‑24 |
Deprivation and Core20
Deprivation averages decile 6.4 PCN-wide but spans a 72.7 percentage-point practice range
Warrington Innovation PCN's Core20 share is 15.1%, below Warrington (LAD) (16.9%), NHS Cheshire and Merseyside Integrated Care Board (31.9%), and England (21.0%), with an average IMD decile of 6.4. Practice shares span 72.7 pp, yielding a 19.4% weighted share. Highest concentration sits at 4 Seasons Medical Centre (72.65%; 1,619 estimated patients), whereas highest volume is at Springfields Medical Centre (41.19%; 3,533 estimated patients). Denominators diverge between 9,534 registered practice estimates and 5,922 associated residents. Targeting must balance high-concentration outreach with high-volume clinical review capacity.
% of patients in IMD quintile 1, by practice
Dashed line: England 21.0% · right column: Core20 patients, registered basis
PLUS groups and inclusion health
PLUS groups and inclusion health
524
SMI register
1.08% recorded prevalence
270
Learning disability register
0.56% recorded prevalence
31
Care homes, 1,250 beds
In the PCN catchment
9.4%
Provide unpaid care
Warrington (LAD), Census 2021
Recorded registers include 524 patients with severe mental illness (1.1%) and 270 with learning disabilities (0.6%), compared with Warrington (LAD) (1.0% and 0.5%), NHS Cheshire and Merseyside Integrated Care Board (1.1% and 0.6%), and England (1.0% and 0.6%). The catchment area includes 31 care homes with 1,250 beds. Crude register prevalence and site bed capacity do not establish unmet need or resident patient occupancy.
Severe mental illness: physical health checks
Across 524 SMI patients, three-year monitoring fell while England rose: BMI recording dropped 3.6 pp (England +5.1 pp) and blood pressure checks fell 1.7 pp (England +4.4 pp). These declines could widen physical-health inequalities, which audits can test.
Clinical focus: hypertension and lipids
Clinical focus: hypertension and lipids
7,262
Hypertension register
+5.89%
Register growth, 3 yrs
Warrington (LAD) +6.41% · England +5.60%
+1.73pp
BP control, under 80
≤140/90 · +2.05pp aged 80+
+1,193
More patients by 2030
Forecast 8,455 (16.74%)
Hypertension case-finding and control
Recorded hypertension prevalence is 14.9% across 7,262 registered patients, below Warrington (16.4%), NHS Cheshire and Merseyside ICB (16.8%) and England (15.2%). Practice prevalence ranges from 10.1% at Chapelford Primary Care Centre to 17.4% at Culcheth Medical Centre. An unadjusted benchmark model indicates an illustrative gap range of +213 to +791 patients against England and Warrington (LAD), though crude prevalence does not establish under-detection. For recorded patients, 89.2% have a recent blood pressure reading (Warrington 86.2%, England 90.0%) and 70.1% are treated to target, exceeding Warrington (68.7%) and ICB (69.1%) rates. Lower recorded prevalence alongside strong blood pressure control suggests case-finding audits could help identify undiagnosed hypertensive patients in lower-prevalence practices.
Lipids and statins
Lipid-lowering therapy uptake in QRISK ≥ 20% patients is 60.8% (England 63.6%). Statin therapy also trails England across diabetes without CVD (68.2% vs 73.2%), diabetes with CVD (79.9% vs 84.4%) and CKD (67.9% vs 70.3%). Fewer at-risk patients receive lipid-lowering therapy than England rates imply, highlighting a priority to audit high-risk treatment initiation.
| Measure | Items | Cost / item | ICB | England | Annual spend |
|---|---|---|---|---|---|
| Lipid-modifying, 2026 | 79,281 | £1.70 | £1.71 | £1.86 | £134,778 |
| Cardiovascular (all), 2025 | 111,730 | £4.73 | £4.37 | £3.33 | £528,483 |
In 2026, the PCN prescribed 79,281 lipid-modifying items (£134,778 spend) at £1.70 per item (England £1.86), spending £12,685 less than at England's unit cost. Lower unit costs than England mean average cost per item is below national benchmarks across 79,281 items.
Clinical focus: respiratory, cancer register and children
Clinical focus: respiratory, cancer register and children
Respiratory
+0.44%
Asthma reviews, PCN 3-yr % change
+4.44%
Asthma reviews, England 3-yr % change
−1.19%
Asthma prevalence, PCN 3-yr % change
Asthma prevalence is 6.7% across 3,084 patients, yet annual review completion is 61.6% (Warrington (LAD) 61.4%, England 65.7%), indicating an unreviewed scale of 1,185 patients. Over three years, asthma reviews changed by +0.4% (England +4.4%). Asthma prescribing for ages 5–19 is 1,285 per 1,000 (England 1,488). Recorded COPD prevalence is 1.8% (869 patients), with review completion at 67.8% trailing Warrington (LAD) (72.3%) and England (76.4%). Lower review rates could reflect recall barriers, which practice audits can evaluate.
Cancer register and children's immunisation
Cancer recorded prevalence is 3.4% (1,646 patients), below England (3.8%). In Q1 2025/26, MMR coverage at age 5 dropped 2.4 pp from 96.8% for dose 1 to 94.4% for dose 2, falling 0.6 pp below the 95.0% target across a cohort of 126 children. At 24 months, MMR1 and 6-in-1 coverage reached 91.4%. This dose gap could leave children incompletely protected before school entry.
Dashed line: 95% national coverage target · solid tick: England
Early cancer diagnosis
Early cancer diagnosis
55.5%
Cheshire and Merseyside ICB, stage 1–2
55.3%
England, 2022
75%
National ambition by 2028
~2,640
Extra early-stage cases a year to reach the ambition
| Stage 1–2 share by cancer type, 2022 | Cheshire and Merseyside ICB | England | No usable stage | Staged cancers |
|---|---|---|---|---|
| Lung | 40.4% | 33.8% | 11% | 2,354 |
| Breast | 87.1% | 85.4% | 11% | 2,083 |
| Prostate | 52.3% | 53.2% | 12% | 2,037 |
| Bowel | 44.9% | 47.0% | 16% | 1,674 |
| Skin cancer | 86.9% | 87.8% | 21% | 932 |
Across NHS Cheshire and Merseyside ICB in 2022, 55.5% of cancers with a known stage (7,482 of 13,490; 72.8% staged) were diagnosed at stage 1 or 2, against 55.3% in England, below the 75.0% national ambition by 2028 and requiring about 2,640 extra early diagnoses annually. System stage metrics reflect wider geography, not PCN performance. In Warrington Innovation PCN, cervical screening coverage (aged 25–49) is 69.6% (England 66.8%), but three-year change fell 1.5% (England -1.0%), varying from 56.0% at 4 Seasons Medical Centre to 77.7% at Culcheth Medical Centre. Lagging screening uptake at lower-performing practices may hinder early detection across the local care pathway.
Cancer waits, diagnostics and community services
Cancer waits, diagnostics and community services
Cancer waits and diagnostics, Jul 2026 (provisional)
For North Cheshire and Mersey NHS Foundation Trust in provisional July 2026 data, 62-day cancer referral to treatment reached 83.7% (85.0% standard), above Mersey and West Lancashire Teaching Hospitals NHS Trust (78.0%), NHS Cheshire and Merseyside Integrated Care Board (76.2%), Manchester University NHS Foundation Trust (72.8%) and England (71.2%). The 28-day faster diagnosis standard was 80.2% (standard 75.0%). Diagnostic waits of 6+ weeks were 0.5% for MRI and 2.3% for CT, below Manchester University NHS Foundation Trust (11.7% and 14.7%) and England (21.4% and 9.9%). Provider data reflects hospital activity, not PCN performance.
| Pathways within standard (%) | North Cheshire and Mersey | Mersey and West Lancashire | Manchester | Cheshire and Merseyside ICB | England |
|---|---|---|---|---|---|
| 28-day faster diagnosis (75%) | 80.21 | 72.39 | 80.06 | 77.25 | 79.32 |
| 31-day treatment (96%) | 98.17 | 95.46 | 92.54 | 95.71 | 92.50 |
| 62-day referral to treatment (85%) | 83.67 | 77.96 | 72.85 | 76.23 | 71.16 |
| Diagnostic waits over 6 weeks (%) | North Cheshire and Mersey | Mersey and West Lancashire | Manchester | England |
|---|---|---|---|---|
| MRI | 0.53 | 14.04 | 11.68 | 21.40 |
| CT | 2.32 | 13.08 | 14.66 | 9.92 |
| Echocardiography | 28.04 | 34.88 | 4.91 | 28.48 |
| Colonoscopy | 15.98 | 18.04 | 4.51 | 30.83 |
| Gastroscopy | 20.24 | 18.17 | 29.35 | 29.02 |
| All 15 DM01 tests | 6.34 | 21.17 | 8.98 | 23.14 |
| Community services activity | Warrington residents | Cheshire and Merseyside ICB |
|---|---|---|
| Care contacts | 38,550 | 541,280 |
| Referrals | 7,320 | 97,150 |
| Patients with a contact | 14,830 | 146,240 |
Community services (residents of Warrington), Jun 2026 (provisional). In provisional June 2026 community services data for Warrington residents, 56% of all recorded community contacts (21,595 of 38,550) were with adults aged 65 and over. These figures reflect borough resident activity across community service providers and are not captured at PCN level.
Practice variation and patient experience
Practice phone access spans 37.2 pp and overall good experience spans 28.4 pp
In 2025/26, QOF overall achievement spans from 73.7% at 4 Seasons Medical Centre to 99.2% at Culcheth Medical Centre (England 92.5%). Vaccination and immunisation achievement shows a 76.4 pp spread, from 20.6% at Parkview Medical Centre to 97.0% at Culcheth Medical Centre (England 55.2%). Personalised care adjustment rates across all domains reach 15.3% at 4 Seasons Medical Centre (England 10.0%).
GP Patient Survey by practice
| Practice | Responses | % in IMD Q1 | Phone easy | Request led to appt | Overall good |
|---|---|---|---|---|---|
| Guardian Street | 126 | 21.8 | 63.9% | 76.7% | 84.1% |
| Springfields | 150 | 41.2 | 68.5% | 75.0% | 84.1% |
| Culcheth | 120 | 0.0 | 53.8% | 71.3% | 80.9% |
| Parkview | 115 | 34.3 | 69.5% | 69.7% | 72.7% |
| 4 Seasons | 98 | 72.7 | 42.8% | 48.4% | 58.6% |
| Chapelford | 103 | 0.0 | 32.4% | 58.5% | 55.7% |
| England | — | ~21 | 56.9% | 71.6% | 76.7% |
Where the PCN lags
Sixteen of 25 measures trail England's three-year change, led by heart failure reviews
Across 25 measures, 16 trail England's three-year change. Heart failure functional reviews fell 7.5% (England +8.7%), while physical health checks across the 524 patients on the severe mental illness register dropped: BMI recording fell 3.6 pp (England +5.1 pp), alcohol recording fell 2.1 pp (England +5.4 pp), and blood pressure checks fell 1.7 pp (England +4.4 pp). Conversely, smoking cessation offers rose 3.9 pp (England +0.1 pp) and lipid-lowering therapy in QRISK ≥ 20% grew 8.0% (England +6.2%). Falling review trajectories may reflect recall or appointment barriers, which clinical pathway audits can test.
3-year change · PCN vs England
Bars show the direction and scale of relative change. Orange: PCN · Grey: England.
Heart failure reviews
BMI record (SMI)
Alcohol record (psychosis)
BP check (SMI)
Asthma reviews
Smoking support (SMI)
Diabetes statin (no CVD)
QRISK statin treatment
What the data can't tell us: gaps and local assets
What the data can't tell us: gaps and local assets
| Local assets and voluntary sector | PCN | Warrington (LAD) | Asset | PCN | Warrington (LAD) |
|---|---|---|---|---|---|
| Care homes (catchment) | 31 (1,250 beds) | n/a | Schools (catchment) | 79 | n/a |
| Children's centres | 6 | 12 | Places of worship | 54 | 89 |
| Libraries | 4 | 7 | Primary schools (LA maintained) | 16 | 28 |
| Primary academies | 17 | 31 | Special schools | n/a | 1 |
0 = the source returned zero. n/a = not held at this level. No data = no value returned; this does not mean zero.
Options for the PCN
Options for the PCN
Each option in full
Option 1
Hypertension case-finding and register audit
Recorded hypertension prevalence is 14.9% (7,262 patients on a 49,082 list) against 15.2% in England and 16.4% in Warrington (LAD), giving an unadjusted range of +213 to +791. For discussion: practices could run searches for repeated raised blood pressure readings without a diagnosis code and offer opportunistic checks. Moderate effort to run.
Evidence base: the hypertension register is the cohort for case-finding, blood-pressure control and AF anticoagulation; its size and growth set the workload those interventions must cover, and a shortfall in control shows up later as emergency admission.
Policy anchor: Core20PLUS5 (hypertension case-finding and optimal management); NHS CVD ambitions to 2029 on detection, treatment to target and statins for high-risk patients (CVDPREVENT).
Option 2
Structured asthma annual review recall
Asthma annual review completion is 61.6% across the 3,084-patient register against 65.7% in England (4.1 pp below England), indicating a scale of 1,185 unreviewed patients. For discussion: practices could standardise asthma recall templates, align inhaler prescribing checks with annual reviews, and test after-school or holiday slots. Moderate effort to run.
Evidence base: the annual asthma review is the process gap between the register and outcomes.
Policy anchor: Core20PLUS5 chronic respiratory disease priority.
Option 3
SMI physical health check consolidation
On the 524-patient SMI register, three-year checks fell: BMI by 3.6 pp (England +5.1 pp), alcohol by 2.1 pp (England +5.4 pp), and BP by 1.7 pp (England +4.4 pp). For discussion: practices could audit partial-check coding, offer single-visit physical health checks, and raise shared-care reconciliation with system partners. Moderate effort to run.
Evidence base: the SMI register is the cohort for the annual physical health check; the alcohol record is the delivery measure for alcohol screening and brief intervention.
Policy anchor: Mental Health Investment Standard; NHS alcohol care teams and the From Harm to Hope strategy.
Provenance and audit trail
Provenance and audit trail
Figures are the profile's, drawn from Coplug indicator tables: census, deprivation and QOF measures, MHCLG, Rough sleeping snapshot in England: autumn 2025, OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) and OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002). Every recommended action and option is the profile's own; the evidence-base statements that support them — what each register is the cohort for, and the national policy it serves — are quoted from Coplug's indicator catalogue. No recommendation in this report is authored outside the profile and that catalogue. ICB- and provider-level data (page 8) describes the system the PCN sits in and is not read as PCN performance.
| Recommendation | Indicator(s) | Policy anchor | Data level |
|---|---|---|---|
| Two-track Core20 outreach (p3) | Core20 cohort (IMD quintile 1) | Core20PLUS5 · 10YHP equity test | PCN |
| SMI physical health check audit (p4) | Record of BMI in the last 12 months for patients on the MH register (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN |
| Hypertension case finding audit (p5) | Hypertension: QOF prevalence | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN |
| Preschool MMR second dose recall (p6) | MMR dose 2 coverage at age 5 | 10YHP sickness to prevention · 95% target | PCN |
| Targeted cervical screening recall (p7) | Women (25-49 yrs) with a record of cervical screening in the last 3.5 yrs (denominator incl. PCAs) | Fit for the Future: 10 Year Health Plan for England · Medium Term Planning Framework 2026 | PCN |
| Access and triage workflow review (p9) | GPPS easy to contact the practice by phone | 10YHP, hospital to community | Practice |
| Option 1 · Hypertension case-finding and register audit (p12) | Hypertension register · Hypertension: QOF prevalence · Registered population | Core20PLUS5 CVD · CVDPREVENT 2029 | PCN & Practice |
| Option 2 · Structured asthma annual review recall (p12) | Asthma register · Patients with Asthma: review in the last 12 months (denominator incl. PCAs) | Core20PLUS5 respiratory | PCN |
| Option 3 · SMI physical health check consolidation (p12) | Severe mental illness register · SMI register with a BP check in the last 12 months · Record of a BP check in the last 12 months for patients on the MH register (denominator incl. PCAs) | MHIS · From Harm to Hope | PCN |
Data sources
Data sources
Every figure in this profile comes from a dataset below, at the level and period stated. Nothing published above PCN level is read as PCN performance.
| Dataset | Level | Period | Used for |
|---|---|---|---|
| Coplug indicator tables: census, deprivation and QOF measures | PCN & Practice | 2023 to 2025, projected to 2030; 2023 to 2024 | Pages 1, 2, 3, 4, 5, 6, 7, 8, 10, 12 |
| MHCLG, Rough sleeping snapshot in England: autumn 2025 | Local authority | Autumn 2025 | Pages 2, 4 |
| OHID, Fingertips diabetes by frailty status: HbA1c control (93712, 93713) | PCN | 2024/25 | Pages 2, 4 |
| OHID, Fingertips falls: emergency admissions, 65+ and 65 to 79 (22401, 22402), accidental-fall deaths (94002) | Local authority | 2024/25; 2022-24 | Pages 2, 4 |
| ONS, Census 2021 TS039: provision of unpaid care (age-standardised) | Local authority | Census 2021 | Pages 2, 4 |
| QOF registers, prevalence and care processes (Coplug indicator tables) | Practice | 2023 to 2025, projected to 2030 | Pages 4, 5, 6, 7, 8, 10 |
| UKHSA, COVER supplementary GP data, childhood immunisation coverage, Q1 2025/26 | PCN & Practice | Q1 2025/26 | Pages 4, 6 |
| UKHSA, Seasonal influenza vaccine uptake in GP patients, 2025 to 2026 | Local authority | 2025/26 season to 28 Feb 2026 | Pages 4, 6 |
| NHS England, Cancer Waiting Times: July 2026 monthly time series with revisions | ICB & Provider | Jul 2026 (provisional) | Pages 7, 8 |
| NHS England, Community Services Statistics (CSDS): June 2026 provisional experimental data | ICB & Local authority | Jun 2026 (provisional) | Pages 7, 8 |
| NHS England, Monthly Diagnostics Waiting Times and Activity (DM01): provider by test, July 2026 | Provider | Jul 2026 | Pages 7, 8 |
| National Disease Registration Service, Stage at diagnosis by cancer site in England, 2013 to 2022 | ICB | 2022 | Pages 7, 8 |
| NHS England / Ipsos, GP Patient Survey 2026: practice results (weighted) | Practice | Survey Jan-Apr 2026 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: achievement by practice and domain | Practice | 2025/26 | Page 9 |
| NHS England, Quality and Outcomes Framework 2025-26: personalised care adjustments by practice and domain | Practice | 2025/26 | Page 9 |
| Coplug indicator catalogue — definitions, cohorts, policy anchors | Reference | Current | Evidence-base lines, page 13 |
Methods, data-quality notes and limitations
Methods, data-quality notes and limitations
Methods
Estimated gaps apply benchmark prevalence to the registered population and subtract the recorded register. They size the task; they are not confirmed missed patients.
Percentage points are the difference between two rates; a relative change is that difference as a share of the starting rate. Register changes are relative, over three years.
Forecasts to 2030 extend each indicator's current trajectory with no change in case-finding or service model: a baseline to act against, not a prediction.
Core20 is the most deprived 20% nationally (IMD quintile 1). Practice shares are not additive to the PCN figure. Ethnic minority is 100% minus White. Local-authority averages are unweighted.
